Zachary Fetters

Zachary Fetters serves as a primary contracting professional within the National Institute of Allergy and Infectious Diseases (NIAID), where he plays a critical role in advancing biomedical research through strategic acquisitions of scientific and technical services. He manages a portfolio focused on research and development contracts supporting the institute’s mission to combat infectious, immunologic, and allergic diseases. His acquisitions typically involve high-containment laboratory infrastructure, diagnostic tool development, and biosafety-enhancing technologies, aligning with NIAID’s priority to strengthen preparedness for emerging public health threats. Fetters works closely with scientific and operational teams to ensure procurement strategies directly support mission-critical research objectives. His primary contractor relationships center on Quality Biological, Inc., a leading provider of biological reference materials and diagnostic reagents, and Genomic Labs Ltd., a specialized firm in genomic sequencing and bioanalytical services. These partnerships reflect a preference for vendors with deep expertise in biosafety-compliant product development and high-complexity laboratory support. Fetters consistently engages with contractors capable of delivering GMP-grade materials and validated analytical platforms, fostering long-term collaborations that ensure supply chain reliability for time-sensitive public health initiatives. Fetters’ contracting approach prioritizes broad market access, with 75% of acquisitions conducted under open competition and 25% designated as total small business set-asides under FAR 19.5. While he does not routinely utilize 8(a), HUBZone, or SDVOSB set-asides, his consistent allocation of quarter of awards to small businesses demonstrates a structured commitment to socioeconomic inclusion and market diversification within the biomedical research ecosystem. His procurement focus is concentrated in NAICS 541715 (Research and Development in Life Sciences) and 541714 (Biotechnology R&D), with additional emphasis on 334516 (Analytical Laboratory Instrument Manufacturing). He regularly procures next-generation sequencing systems, biosafety cabinet integrations, pathogen detection platforms, and custom assay development services, reflecting deep technical expertise in infectious disease diagnostics, immunological assay validation, and laboratory automation technologies.